GlassScriptPhysician profile
David M Tonkin
NPI 1760438642
$13,994.95
in general payments reported to CMS, 2019-2025
32 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 87% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $1,004 · 2021: $776 · 2022: $540 · 2023: $4,828 · 2024: $2,165 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,875 · Travel and Lodging: $4,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,874.60 |
| Travel and Lodging | $4,511.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $4,055.50 | 2023-2025 | Prospera, Biotronik |
| Boston Scientific Corporation | $4,026.08 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Pain Management |
| Abbott Laboratories | $2,577.24 | 2019-2025 | Proclaim, Eterna, Axium |
| Nevro Corp. | $789.21 | 2019-2024 | Senza |
| Medtronic, INC. | $767.83 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Accurian |
| Medtronic USA, INC. | $630.39 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $228.96 | 2019-2025 | Belbuca, Xtampza |
| Indivior INC. | $171.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $112.36 | 2023-2025 | Spravato |
| Genzyme Corporation | $86.78 | 2023-2025 | |
| Nalu Medical, INC. | $71.90 | 2021 | |
| Saluda Medical Americas, INC. | $71.36 | 2024 | Evoke |
| Coloplast Corp | $54.01 | 2021 | |
| Si-Bone, INC. | $44.27 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.64 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $27.26 | 2019-2020 | |
| Pfizer INC. | $24.32 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $21.02 | 2025 | |
| Daiichi Sankyo INC. | $20.60 | 2019 | |
| Emd Serono, INC. | $18.37 | 2022 | |
| Painteq LLC | $17.60 | 2024 | Painteq |
| Averitas Pharma INC. | $17.05 | 2023 | Qutenza |
| Lundbeck LLC | $16.31 | 2021 | |
| Novo Nordisk INC | $14.92 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.25 | 2025 | Trintellix |
| Biodelivery Sciences International, INC. | $13.51 | 2019 | |
| Alkermes, INC. | $13.49 | 2025 | Aristada, Lybalvi |
| Zyla Life Sciences, INC. | $13.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.41 | 2021 | |
| Lilly USA, LLC | $12.21 | 2019 | |
| Allergan, INC. | $11.38 | 2021 | |
| Spinal Simplicity, LLC | $9.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tonkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.